

## References

---

### 7. References

1. Santos NP, Colaco AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: A Review. *Tumor Biology*. 2017 Mar; 39(3):1-20.
2. Waller LP, Deshpande V, Pysopoulos N. Hepatocellular carcinoma: A comprehensive review. *World journal of hepatology*. 2015 Nov 18; 7(26):2648-2663.
3. Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. *World journal of clinical oncology*. 2017 Jun 10; 8(3):203-213.
4. Lokesh KN, Chaudhuri T, Lakshmaiah KC, Babu KG, Dasappa L, Jacob LA, Babu MS, Rudresha AH, Rajeev LK. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases. *Indian journal of cancer*. 2017 Jul 1; 54(3):526.
5. Torrecilla S, Sia D, Harrington AN, et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. *J Hepatol* 2017; 67:1222-1231.
6. Li Y, Li H, Spitsbergen JM, Gong Z. Males develop faster and more severe hepatocellular carcinoma than females in *kras* V12 transgenic zebrafish. *Scientific reports*. 2017 Jan 24; 7(1):41280.
7. Zhang K, Wang T, Zhou H, Feng B, Chen Y, Zhi Y, Wang R. A novel aurora-A inhibitor (MLN8237) synergistically enhances the antitumor activity of sorafenib in hepatocellular carcinoma. *Molecular Therapy-Nucleic Acids*. 2018 Dec 7; 13:176-188.
8. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med*. 1996; 334(11):693–699.
9. Gosalia AJ, Martin P, Jones PD. Advances and Future Directions in the Treatment of Hepatocellular Carcinoma. *Gastroenterol Hepatol (N Y)*. 2017 Jul; 13(7):398-410.
10. Livraghi T, Festi D, Monti F, Salmi A, Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. *Radiology*. 1986; 161(2):309–312.
11. Crissien AM, Frenette C. Current management of hepatocellular carcinoma. *Gastroenterol Hepatol (N Y)* 2014; 10(3):153–161.
12. Sato M, Watanabe Y, Ueda S, et al. Microwave coagulation therapy for hepatocellular carcinoma. *Gastroenterology*. 1996;110(5):1507–1514

## References

---

13. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. *Dig Liver Dis.* 2016; 48(6):571–577.
14. Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. *Semin Intervent Radiol.* 2011; 28(2):207–211.
15. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC., II Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. *J Surg Oncol.* 2013; 107(5):544–549.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M. Sorafenib in advanced hepatocellular carcinoma. *New England journal of medicine.* 2008 Jul 24;359(4):378-390.
17. WHO, IUCN and WWF, Guidelines on the conservation of medicinal plants, (IUCN Gland Switzerland), (1993).
18. Katkar KV, Suthar AC, Chauhan VS. The chemistry, pharmacologic, and therapeutic applications of *Polyalthia longifolia*. *Pharmacogn Rev.* 2010 Jan;4(7):62-68.
19. Velavan S, Nagulendran KR, Mahesh R, Begum VH. *Phcog Rev.:* plant review the chemistry, pharmacological and therapeutic applications of *Asparagus racemosus*-a review. *Pharmacognosy Reviews.* 2007 Jul;1(2):350-360.
20. Kotnis MS, Patel P, Menon SN, Sane RT. Renoprotective effect of *Hemidesmus indicus*, a herbal drug used in gentamicin-induced renal toxicity. *Nephrology.* 2004 Jun; 9(3):142-152.
21. Bhagwati Uniyal, Utilization of medicinal plants by the rural women of Kulu, Himachal Pradesh. *Indian Journal of Traditional Knowledge.* 2003; 2(4): 366-370.
22. Singh BN, Singh BR, Sarma BK, Singh HB. Potential chemoprevention of N-nitrosodiethylamine-induced hepatocarcinogenesis by polyphenolics from *Acacia nilotica* bark. *Chemico-biological interactions.* 2009 Sep 14; 181(1):20-28.
23. Kim DB, Lee DK, Cheon C, Ribeiro RI, Kim B. Natural products for liver cancer treatment: From traditional medicine to modern drug Discovery. *Nutrients.* 2022 Oct 12;14(20):4252.
24. Wang Y, Li J, Xia L. Plant-derived natural products and combination therapy in liver cancer. *Frontiers in Oncology.* 2023 Feb 14; 13:1116532.

## References

---

25. Sherman M, Bruix J, Porayko M, Tran T, AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. *Hepatology*. 2012 Sep; 56(3):793-796.
26. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. *The Lancet*. 2009; 373(9664):614.
27. Rawat D, Shrivastava S, Naik RA, Chhonker SK, Mehrotra A, Koiri RK. An overview of natural plant products in the treatment of hepatocellular carcinoma. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*. 2018 Oct 1;18(13):1838-1859.
28. Hassan HA, El-Gharib NE, Azhari AF. Role of natural antioxidants in the therapeutic management of hepatocellular carcinoma. *Hepatoma Res*. 2016; 2:216-3.
29. Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, Nasti G, Fisichella R, Romano C, De Divitiis C, Taibi R, Fiorica F, Di Francia R, Di Mari A, Del Pup L, Crispo A, De Paoli P, Santorelli A, Quagliariello V, Iaffaioli RV, Tirelli U, Facchini G. Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. *Oncotarget*. 2017 Apr 11;8(15):24401-24414.
30. Goyal BR, Goyal RK, Mehta AA. PHCOG rev.: plant review phyto-pharmacology of *Achyranthes aspera*: a review. *Pharmacogn Rev*. 2007 Jan;1(1):143-150.
31. Arora S, Tandon S. *Achyranthes aspera* root extracts induce human colon cancer cell (COLO-205) death by triggering the mitochondrial apoptosis pathway and S phase cell cycle arrest. *The Scientific World Journal*. 2014; 2014.
32. Subbarayan PR, Sarkar M, Rao SN, Philip S, Kumar P, Altman N, Reis I, Ahmed M, Ardalan B, Lokeshwar BL. *Achyranthes aspera* (Apamarg) leaf extract inhibits human pancreatic tumor growth in athymic mice by apoptosis. *Journal of Ethnopharmacology*. 2012 Jul 13; 142(2):523-530.
33. Subbarayan PR, Sarkar M, Impellizzeri S, Raymo F, Lokeshwar BL, Kumar P, Agarwal RP, Ardalan B. Anti-proliferative and anti-cancer properties of *Achyranthes aspera*: specific inhibitory activity against pancreatic cancer cells. *Journal of ethnopharmacology*. 2010 Aug 19;131(1):78-82.
34. Lakshmi V, Srivastava AK. Antidiabetic Potential of the Roots of the *Achyranthes Aspera* Linn *Ann Clin Pharmacol Toxicol*. 2019; 1(1): 1005.

## References

---

35. Singh RK, Verma PK, Kumar A, Kumar S, Acharya A. *Achyranthes aspera* L. leaf extract induced anticancer effects on Dalton's Lymphoma via regulation of PKC $\alpha$  signaling pathway and mitochondrial apoptosis. *Journal of Ethnopharmacology*. 2021 Jun 28; 274:114060.
36. Kartik R, Rao CV, Trivedi SP, Pushpangadan P, Reddy GD. Amelioration effects against N-nitrosodiethylamine and CCl<sub>4</sub>-induced hepatocarcinogenesis in Swiss albino rats by whole plant extract of *Achyranthes aspera*. *Indian journal of pharmacology*. 2010 Nov 1; 42(6):370-375
37. Beedimani RS, Jeevangi SK. Evaluation of hepatoprotective activity of *Boerhaavia diffusa* against carbon tetrachloride induced liver toxicity in albino rats. *Int J Basic Clin Pharmacol*. 2015 Jan; 4:153-158.
38. Rawat AK, Mehrotra S, Tripathi SC, Shome U. Hepatoprotective activity of *Boerhaavia diffusa* L. roots a popular Indian ethnomedicine. *Journal of Ethnopharmacology*. 1997 Mar 1; 56(1):61-66.
39. Kuruppu AI, Paranagama P, Goonasekara CL. Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka. *Saudi Pharmaceutical Journal*. 2019 May 1; 27(4):565-573.
40. Rakhi S, Daman S, Bilikere S D, Madhu C. Inhibition of human cervical cancer cell growth by ethanolic extract of *Boerhaavia diffusa* Linn.(Punarnava) root. *Evidence-Based Complementary and Alternative Medicine*. 2010; 2011.
41. Venkatajothi R. In-vitro anticancer activity of *Boerhaavia diffusa* Linn. *Int J Curr Res Biol Med*. 2017; 2:20-24.
42. Kayande N, Kushwah P. Invitro and In Vivo Evaluation of Anticancer Activity of *Boerhaavia Diffusa* Linn in Experimental Animals. *PharmaTutor*. 2014 May 1;2(5):133-137.
43. Sreeja S, Sreeja S. An in vitro study on antiproliferative and antiestrogenic effects of *Boerhaavia diffusa* L. extracts. *Journal of ethnopharmacology*. 2009 Nov 12; 126(2):221-225.
44. Leyon PV, Lini CC, Kuttan G. Inhibitory effect of *Boerhaavia diffusa* on experimental metastasis by B16F10 melanoma in C57BL/6 mice. *Life Sciences*. 2005 Feb 4; 76(12):1339-1349.

## References

---

45. Vigneswaran M, Prem Kumar G, Sivakumar S, Siva G, Nandakumaran T, Lakshmi Prabha A, Jayabalan NA. Compendious review of *Enicostemma littorale* Blume. Panacea to several maladies. International Journal of Scientific & Engineering Research. 2017;8(6):1817-1836.
46. Vasu VT, Ashwinikumar C, Maroo J, Gupta S, Gupta S. Antidiabetic effect of *Enicostemma littorale* Blume aqueous extract in newly diagnosed non-insulin-dependent diabetes mellitus patients (NIDDM): a preliminary investigation. Oriental Pharmacy and Experimental Medicine. 2003 Jan;3(2):84-90.
47. Rajasekaran D, Manoharan S, Prabhakar MM, Manimaran A. *Enicostemma littorale* prevents tumor formation in 7, 12-dimethylbenz (a) anthracene-induced hamster buccal pouch carcinogenesis. Human & experimental toxicology. 2015 Sep; 34(9):911-921.
48. Kavimani S, Manisenthkumar KT. Effect of methanolic extract of *Enicostemma littorale* on Dalton's ascitic lymphoma. Journal of ethnopharmacology. 2000 Jul 1; 71(1-2):349-352.
49. Debnath P, Karan S, Chatterjee TK. In-vivo anticancer activity of methanoal extract of the whole medicinal plant *Enicostemma littorale* in swiss albino mice, Pharmacologyonline.2010. 3: 637-643.
50. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Correction to: Hepatocellular carcinoma (Nature Reviews Disease Primers, (2021), 7, 1, (6). Nature Reviews Disease Primers. 2024 Dec; 10(1):10.
51. Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017 Apr 1; 18(4):863-872.
52. Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Frontiers in Oncology. 2020 Nov 30;10:601710
53. Subhash Waghe. Critical analysis of hepatic cancer in Ayurveda W.S.R. to Yakritodara & Yakrit Gulma. J of Ayurveda and Hol Med (JAHM).2023;11(7):65-71.
54. Augusto Villanueva, Hepatocellular Carcinoma, N Engl J Med 2019;380:1450-1462
55. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer 2012; 48:2125-2136.

## References

---

56. Yoon SK. Molecular mechanism of hepatocellular carcinoma. *Hepatoma Research*. 2018 Aug 8; 4(8):42.
57. Chan C, Wang Y, Chow PK, Chung AY, Ooi LL, Lee CG. Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein. *Mol Cell Biol* 2013; 33:485-497.
58. Yun C, Um HR, Jin YH, Wang JH, Lee MO, Park S, Lee JH, Cho H. NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. *Cancer Lett* 2002; 184: 97-104.
59. Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. *Mol Cell Biol* 1997; 17:6427-6436.
60. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. *Proc Natl Acad Sci USA* 1994; 91:10350-10354.
61. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. *J Biol Chem* 2001; 276:16969-16977.
62. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. *Hepatology* 2004; 39:1683-1693.
63. Tacke RS, Tosello-Tramont A, Nguyen V, Mullins DW, Hahn YS. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. *J Biol Chem* 2011; 286:10847-10855.
64. Yu GY, He G, Li CY, Tang M, Grivennikov S, Tsai WT, Wu MS, Hsu CW, Tsai Y, Wang LH, Karin M. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. *Mol Cell* 2012; 48:313-321.
65. Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. *Clin Liver Dis* 2012; 16:659-666.
66. Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. *Clin Liver Dis* 2018; 22:11-21.

## References

---

67. Agosti P, Sabba C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. *Biochim Biophys Acta* 2018; 1864:607-617.
68. Wu J. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma. *Oncotarget* 2016; 7:42762-42776.
69. Ding J, Wu J. Epigenetic regulation of hepatic tumor-initiating cells. *Front Biosci (Landmark Ed)* 2015; 20:946-963.
70. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. *Gut* 2010; 59:1303-1307.
71. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* 2010; 140:197-208.
72. Panneerselvam S, Wilson C, Kumar P, Abirami D, Pamarthi J, Reddy MS, Varghese J. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options. *Cell Adhesion & Migration*. 2023 Dec 31; 17(1):1-21.
73. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. *Oncogene*. 2003; 22:5093-5107
74. Ho DW, Lo RC, Chan LK, Ng IO. Molecular Pathogenesis of Hepatocellular Carcinoma. *Liver Cancer*. 2016 Oct; 5(4):290-302.
75. Alison MR. Liver stem cells: implications for hepatocarcinogenesis. *Stem Cell Rev*. 2005;1:253-260.
76. Dhillon, A.P., Colombari, R., Savage, K., Scheuer, P.J., 1992. An immunohistochemical study of the blood vessels within primary hepatocellular tumours. *Liver* 5, 311e318.
77. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. *Oncologist*. 2010; 15(suppl 4):14-22.
78. Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. *Cancers*. 2020 Feb 20; 12(2):491.
79. Luo X, He X, Zhang X, Zhao X, Zhang Y, Shi Y, Hua S. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. *MedComm*. 2024 Feb; 5(2):e474.
80. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. *Nat Rev Mol Cell Biol*. 2016; 17(10): 611-625.

## References

---

81. Chiu DK, Tse AP, Law CT, Xu IM, Lee D, Chen M, Lai RK, Yuen VW, Cheu JW, Ho DW, Wong CM. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. *Cell Death & Disease*. 2019 Dec 9; 10(12):1-6.
82. Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced Hepatocellular Carcinoma: Current standard and the Future. *Clinical Liver Disease*. 2019 Jan; 13(1): 13-19.
83. Sherman M. Staging for hepatocellular carcinoma: An embarrassment of riches. *Journal of hepatology*. 2016; 64(3):535-536.
84. Tümen, D.; Heumann, P.; Gülow, K.; Demirci, C.-N.; Cosma, L.-S.; Müller, M.; Kandulski, A. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. *Biomedicines* 2022, 10, 3202.
85. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. *Nature reviews Disease primers*. 2021 Jan 21;7(1):1-28.
86. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. *Gastroenterology*. 2002; 122(6):1609-1619.
87. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. *Hpb*. 2005 Mar 1;7(1):26-34.
88. Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. *Am J Gastroenterol*. 2015 Jun;110(6):836-844.
89. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. *The FEBS journal*. 2013 May; 280(10):2471-2476.
90. Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, Zhang Y, Zhang H, Chen K, Cheng P, Wang C. Diagnostic performance of des- $\gamma$ -carboxy prothrombin for hepatocellular carcinoma: a meta-analysis. *Gastroenterology research and practice*. 2014 Oct; 2014.
91. Watanabe Y, Iwamura A, Shimada YJ, Wakai K, Tamakoshi A, Iso H. Transforming growth factor- $\beta$ 1 as a predictor for the development of hepatocellular carcinoma: a nested case–controlled study. *EBioMedicine*. 2016 Oct 1; 12:68-71.

## References

---

92. Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. *PLoS One*. 2015 Oct 6; 10(10):e0140067.
93. Pinto E, Pelizzaro F, Farinati F, Russo FP. Angiogenesis and hepatocellular carcinoma: from molecular mechanisms to systemic therapies. *Medicina*. 2023 Jun 9; 59(6):1115.
94. Tangkijvanich P, Anukulkamkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. *J Clin Gastroenterol* 2000; 31:302–308.
95. Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan DN, Cao X, Han M, Du H, Ye YA. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *PLoS One*. 2020 Feb 13;15(2):e0228857
96. Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. *Liver international*. 2019 Dec; 39(12):2214-2229.
97. Hussaini IM, Musa B, Bello A. The Search for an Alternative Biomarker for the Detection and Diagnosis of Hepatocellular Carcinoma-The Journey So Far. *Bioequivalence & Bioavailability International Journal*, 2017; 1(3):000115.
98. Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. *J Hepatol* 1994; 20:117–121.
99. Donato MT, Tolosa L, Gómez-Lechón MJ. Culture and functional characterization of human hepatoma HepG2 cells. *Protocols in in vitro hepatocyte research*. 2015:77-93.
100. Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, Deng J, Deng Y, Wu Z, Li Q, Song YA. Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials. *Frontiers in Oncology*. 2021 Oct 11; 11:752725.
101. De Luca E, Marino D, Di Maio M. Ramucirumab, a second-line option for patients with hepatocellular carcinoma: A review of the evidence. *Cancer management and research*. 2020 May 20:3721-3729.
102. Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. *Journal of clinical and experimental hepatology*. 2019 Mar 1; 9(2):221-232.

## References

---

103. Ahmad MS, Suardi N, Shukri A, Mohammad H, Oglat AA, Abunahel BM, Mohamed AM, Makhamrah O. Current status regarding tumour progression, surveillance, diagnosis, staging, and treatment of HCC: a literature review. *Journal of Gastroenterology and Hepatology Research*. 2019 Apr 21;8(2):2841-2852.
104. Farasati Far B, Rabie D, Hemati P, Fooladpanjeh P, Faal Hamedanchi N, Broomand Lomer N, Karimi Rouzbahani A, Naimi-Jamal MR. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. *Livers*. 2023; 3(1):121-160.
105. Schafer DF, Sorrell MF. Hepatocellular carcinoma. *Lancet (London, England)*. 1999; 353(9160):1253-1257.
106. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. *Cancer cell*. 2004; 5(3):215-219.
107. Wu L, Tang Z-Y and Li Y. Experimental models of hepatocellular carcinoma: developments and evolution. *J Cancer Res Clin Oncol* 2009; 135(8): 969–981.
108. Hemminki K. Nucleic acid adducts of chemical carcinogens and mutagens. *Arch Toxicol* 1983; 52:249-285.
109. Bazm MA, Naseri L, Khazaei M. Methods of inducing breast cancer in animal models: A systematic review. *World Cancer Research Journal*. 2018 Jan 1; 5(4):e1182.
110. Marra M, Sordelli IM, Lombardi A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. *J Transl Med* 2011; 9: 171.
111. Oliveira PA, Colaço A, Chaves R, et al. Chemical carcinogenesis. *An Acad Bras Cienc* 2007; 79(4): 593–616.
112. Trosko JE. Commentary: is the concept of “tumor promotion” a useful paradigm? *Mol Carcinog* 2001; 30:131-137.
113. Liu Y, Yin T, Feng Y, Cona MM, Huang G, Liu J, Song S, Jiang Y, Xia Q, Swinnen JV, Bormans G. Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. *Quantitative imaging in medicine and surgery*. 2015 Oct; 5(5):708.
114. Hanajiri K, Mitsui H, Maruyama T, Hashimoto N, Sata M, Omata M. Echographic detection of diethylnitrosamine-induced liver tumors in rats and the effect of the intratumoral injection of an inhibitor of c-Jun N-terminal kinase. *J Gastroenterol Hepatol* 2009; 24:866-871.

## References

---

115. Mansour DF, Abdallah HMI, Ibrahim BMM, Hegazy RR, Esmail RSE, Abdel-Salam LO. The Carcinogenic Agent Diethylnitrosamine Induces Early Oxidative Stress, Inflammation and Proliferation in Rat Liver, Stomach and Colon: Protective Effect of Ginger Extract. *Asian Pac J Cancer Prev*. 2019 Aug 1;20(8):2551-2561.
116. Kriek E. Fifty years of research on N-acetyl-2-aminofluorene, one of the most versatile compounds in experimental cancer research. *J Cancer Res Clin Oncol*. 1992; 118(7):481-489.
117. Sánchez-Meza J, Campos-Valdez M, Domínguez-Rosales JA, Godínez-Rubí JM, Rodríguez-Reyes SC, Martínez-López E, Zúñiga-González GM, Sánchez-Orozco LV. Chronic Administration of Diethylnitrosamine and 2-Acetylaminofluorene Induces Hepatocellular Carcinoma in Wistar Rats. *Int J Mol Sci*. 2023 May 7; 24(9):8387.
118. Gao D, Liu J, Yuan J, Wu J, Kuang X, Kong D, Zheng W, Wang G, Sukumar S, Tu Y, Chen C. Intraductal administration of N-methyl-N-nitrosourea as a novel rodent mammary tumor model. *Annals of translational medicine*. 2021 Apr; 9(7):576.
119. Moon RC, Grubbs CJ, Sporn MB. Inhibition of 7, 12-dimethylbenz (a) anthracene-induced mammary carcinogenesis by retinyl acetate. *Cancer Res* 1976; 36:2626–2630.
120. Akhouri V, Kumari M, Kumar A. Therapeutic effect of Aegle marmelos fruit extract against DMBA induced breast cancer in rats. *Scientific reports*. 2020 Oct 22; 10(1):18016.
121. Wang Y, Zhang Z, Yan Y, et al. A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. *Cancer Res* 2004; 64:1647–1654.
122. Hudish TM, Opincariu LI, Mozer AB, Johnson MS, Cleaver TG, Malkoski SP, Merrick DT, Keith RL. N-nitroso-tris-chloroethylurea induces premalignant squamous dysplasia in mice. *Cancer prevention research*. 2012 Feb 1; 5(2):283-289.
123. Gunning WT, Kramer PM, Lubet RA, et al. Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. *Exp Lung Res* 2000; 26(8):757–772.
124. Bosland MC, Schlicht MJ, Horton L, McCormick DL. The MNU plus testosterone rat model of prostate carcinogenesis. *Toxicologic pathology*. 2022 Jun; 50(4):478-496.
125. DiGiovanni J. Multistage carcinogenesis in mouse skin. *Pharmacology & Therapeutics*. 1992; 54(1): 63–128.

## References

---

126. Kong YH, Xu SP. Salidroside prevents skin carcinogenesis induced by DMBA/TPA in a mouse model through suppression of inflammation and promotion of apoptosis. *Oncology reports*. 2018 Jun 1; 39(6):2513-2526.
127. Vasconcelos-Nóbrega C, Colaco A, Lopes C, Oliveira PA. BBN as an urothelial carcinogen. *In Vivo*. 2012 Jul 1; 26(4):727-739.
128. Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. *British journal of cancer*. 2019 Jul; 121(2):101-108.
129. Jung J. Human tumor xenograft models for preclinical assessment of anticancer drug development. *Toxicological research*. 2014 Mar; 30(1):1-5.
130. Lambertucci F, Li S, Motiño O, Montégut L, Nogueira-Recalde U, Chen H, Anagnostopoulos G, Maiuri MC, Kroemer G, Martins I. Orthotopic Model of Hepatocellular Carcinoma in Mice. In *Liver Carcinogenesis: Methods and Protocols* 2024 Feb 6 (pp. 1-13). New York, NY: Springer US.
131. Wu L, Tang Z-Y and Li Y. Experimental models of hepatocellular carcinoma: developments and evolution. *J Cancer Res Clin Oncol* 2009; 135(8): 969–981.
132. Carcamo WC and Nguyen CQ. Advancement in the development of models for hepatitis C research. *J Biomed Biotechnol* 2012; 2012: 346761.
133. Zheng HC, Xue H, Yun WJ. An overview of mouse models of hepatocellular carcinoma. *Infectious Agents and Cancer*. 2023 Sep 5; 18(1):49.
134. Steiger K, Gross N, Widholz SA, Rad R, Weichert W, Mogler C. Genetically engineered mouse models of liver tumorigenesis reveal a wide histological spectrum of neoplastic and non-neoplastic liver lesions. *Cancers*. 2020 Aug 13; 12(8):2265.
135. Kirtikar KR, Basu BD. (1980) *Indian Medicinal Plants*, Vol. 3, Bishen Sing, Mahendra Pal Sing : DehraDun ; 2066 – 2068.
136. Shukla A, Bukhariya V, Mehta J, Bajaj J, Charde R. *Achyranthes aspera* Linn.(Chirchira): a magic herb in folk medicine. *International Journal of Biomedical and Advance Research*. 2011;2(06):228-240.
137. Herbal Pharmacopoeia I. *Indian Herbal Pharmacopoeia, Revised New Edition*, 2002, 12-19, 88-97.
138. Perumalsamy, A., Ignacimuthu, S., Sen, A. Screening of 34 Indian medicinal plants for antibacterial properties, *J. Ethnopharmacol*. 1998. 62, 173–182.

## References

---

139. He X, Wang X, Fang J, Chang Y, Ning N, Guo H, Huang L, Huang X. The genus *Achyranthes*: A review on traditional uses, phytochemistry, and pharmacological activities. *Journal of ethnopharmacology*. 2017 May 5; 203:260-278.
140. Ministry of Health and Family Welfare, 1999. *The Ayurvedic Pharmacopoeia of India*. New Delhi, India, 101.
141. Kothavade PS, Bulani VD, Nagmoti DM, Deshpande PS, Gawali NB, Juvekar AR. Therapeutic effect of saponin rich fraction of *Achyranthes aspera* Linn. on adjuvant-induced arthritis in sprague-dawley rats. *Autoimmune Diseases*. 2015; 2015(1):943645.
142. Zheng W, Lu X, Fu Z, Zhang L, Li X, Xu X, Ren Y, Lu Y, Fu H, Tian J. Identification of candidate synovial membrane biomarkers after *Achyranthes aspera* treatment for rheumatoid arthritis. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*. 2016 Mar 1; 1864(3):308-316.
143. Basu NK, Neogi NC, Srivastava VP. Biological investigation of *Achyranthes aspera* Linn. and its constituent achyranthine. *J Proc Inst Chem*. 1957; 29:161-165.
144. George M, Venkataraman PR, Pandalai KM. Investigations on plant antibiotics. Part II. A search for antibiotic substances in some Indian medicinal plants. *J Sci Ind Res*. 1947, 6B: 42-46.
145. Valsaraj R, Pushpangadan P, Smitt UW, Andersen A, Nyman U. Antimicrobial screening of selected medicinal plants from India. *J Ethnopharmacol*. 1997, 58: 75-83.
146. Khanna AK, Chander R, Singh C, Srivastava AK, Kapoor NK. Hypolipidemic activity of *Achyranthus aspera* Linn in normal and triton induced hyperlipemic rats. *Indian Journal of Experimental Biology*. 1992 Feb 1;30(2):128-130.
147. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Ray C. Screening of Indian plants for biological activity. Part I. *Indian J Exp Biol*. 1968. 6: 232-247.
148. Akhtar MS, Iqbal J. Evaluation of the hypoglycaemic effect of *Achyranthes aspera* in normal and alloxan-diabetic rabbits. *Journal of ethnopharmacology*. 1991 Jan 1; 31(1):49-57.
149. Gupta SS, Verma SC, Ram AK, Tripathi RM. Diuretic effect of the saponin of *Achyranthes aspera* (Apamarga). *Ind J Pharmacol*. 1972, 4: 208-214.
150. Suresh A, Anandan T, Sivanandam G, Veluchamy G. A pilot study of Naayuruvi Kuzhi Thailam in Eraippunoi (bronchial asthma). *J Res Ayur Sidha*. 1985;6: 171-176.

## References

---

151. Vetrichelvan T, Jegadeesan M. Effect of alcohol extract of *Achyranthes aspera* Linn. on acute and subacute inflammation. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2003 Jan; 17(1):77-90.
152. Gokhale AB, Damre AS, Kulkarni KR, Saraf MN. Preliminary evaluation of anti-inflammatory and anti-arthritic activity of *S. lappa*, *A. speciosa* and *A. aspera*. *Phytomedicine*. 2002 Jan 1; 9(5):433-437.
153. He X, Wang X, Fang J, Chang Y, Ning N, Guo H, Huang L, Huang X. The genus *Achyranthes*: A review on traditional uses, phytochemistry, and pharmacological activities. *Journal of ethnopharmacology*. 2017 May 5; 203:260-278.
154. Narayan, C., Kumar, A. Antineoplastic and immunomodulatory effect of polyphenolic components of *Achyranthes aspera* (PCA) extract on urethane induced lung cancer in vivo. *Mol. Biol. Reports*. 2014, 41, 179–191.
155. Das, A.K., Bigoniya, P., Verma, N.K., Rana, A.C., 2012. Gastroprotective effect of *Achyranthes aspera* Linn. leaf on rats. *Asian Pac. J. Trop. Med*. 2012, 5, 197–201.
156. Barua, C. C., Talukdar, A., Begum, S. A., Pathak, D. C., Sarma, D. K., Borah, R. S., Gupta, A. In vivo wound-healing efficacy and antioxidant activity of *Achyranthes aspera* in experimental burns. *Pharm. Biol*. 2012, 50, 892–899.
157. Gunaseelan D, Ali MS, Albert A, Prabhakaran R, Beno DL, Nagarethinam B. Biochemical and molecular anticancer approaches for *Boerhaavia diffusa* root extracts in oral cancer. *Journal of Cancer Research and Therapeutics*. 2022; 18:S244-52.
158. Akhter F, Hashim A, Khan MS, Ahmad S, Iqbal D, Srivastava AK, Siddiqui MH. Antioxidant,  $\alpha$ -amylase inhibitory and oxidative DNA damage protective property of *Boerhaavia diffusa* (Linn.) root. *South African Journal of Botany*. 2013 Sep 1; 88:265-272.
159. Gour R. *Boerhaavia diffusa* Linn plant: a review—one plant with many therapeutic uses. *Int. J Pharm. Sci. Med*. 2021; 6(4):25-41.
160. Mishra S, Aeri V, Gaur PK, Jachak SM. Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: *Boerhavia diffusa* Linn. *BioMed research international*. 2014; 2014(1):808302.

## References

---

161. Pari L, Amarnath Satheesh M. Antidiabetic effect of *Boerhavia diffusa*: effect on serum and tissue lipids in experimental diabetes. *Journal of medicinal food*. 2004 Dec 1; 7(4):472-476.
162. Umamaheswari A, Nuni A, Shreevidya R. Evaluation of antibacterial activity of *Boerhaavia diffusa* L. leaves. *International Journal of Green Pharmacy (IJGP)*. 2010; 4(2): 75-78.
163. Sahu L, Jena S, Swain SS, Sahoo S, Chand PK. Agrobacterium rhizogenes-mediated transformation of a multi-medicinal herb, *Boerhaavia diffusa* L.: optimization of the process and anti-microbial activity against bacterial pathogens causing urinary tract infections. *Frontiers in Life Science*. 2013 Dec 1;7(3-4):197-209.
164. Kant S., Agnihotri M. S., and Dixit K. S. Clinical evaluation of *Boerhaavia diffusa* as an adjuvant in the treatment of pulmonary tuberculosis. *Phytomedica*, 2001. vol. 2, no. 1-2, 89–94.
165. Barton AD, Cerny EA, Tracy KM. Effects of administration of thioacetamide or testosterone on chromosome-associated proteins in rat liver and kidney. *Archives of Biochemistry and Biophysics*. 1965 Jan 1; 109(1):36-40.
166. Chandan BK, Sharma AK, Anand KK. *Boerhaavia diffusa*: a study of its hepatoprotective activity. *Journal of Ethnopharmacology*. 1991 Mar 1; 31(3):299-307.
167. Mungantiwar AA, Nair AM, Kamal KK, Saraf MN. Adaptogenic activity of aqueous extract of the roots of *Boerhaavia diffusalinn*. *Indian drugs*. 1997; 34(4):184-189.
168. Mungantiwar AA, Nair AM, Shinde UA, Dikshit VJ, Saraf MN, Thakur VS, Sainis KB. Studies on the immunomodulatory effects of *Boerhaavia diffusa* alkaloidal fraction. *Journal of ethnopharmacology*. 1999 May 1; 65(2):125-131.
169. Ahmed-Belkacem A, Macalou S, Borrelli F, Capasso R, Fattorusso E, Tagliatela-Scafati O, Di Pietro A. Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. *Journal of Medicinal Chemistry*. 2007 Apr 19; 50(8):1933-1938.
170. Manu KA, Kuttan G. Anti-metastatic potential of Punarnavine, an alkaloid from *Boerhaavia diffusa* Linn. *Immunobiology*. 2009 Apr 1; 214(4):245-55.
171. Bedi PS, Sharma AK, Najmeddin ZM. Study on Anticancer Activity of *Boerhaavia Diffusa* on Wistar Albino Rats Treated with Diethyl Nitrosamine. *Am. J. Pharm Tech Res*. 2019; 9(01), 292-307.

## References

---

172. Saranya R, Thirumalai T, Hemalatha M, Balaji R, David E. Pharmacognosy of *Enicostemma littorale*: A review. Asian Pacific journal of tropical biomedicine. 2013 Jan 1;3(1):79-84.
173. Sanmugarajah V. A review on therapeutic and pharmacognostic properties of vellarugu (*Enicostemma Littorale* blume). International Journal of Ayurveda and Pharma Research. 2020;8(4):47-67.
174. Kumar P, Kumar B, Gairola S. Macroscopic and microscopic characterization of raw herbal drug mamajjaka [*Enicostema axillare* subsp. Littorale (Blume) A. raynal]. Plant Archives. 2021; 21(1): 1661-1666.
175. Rajasekaran A, Arivukkarasu R, Muruges S. Hepatoprotective Effect of *Adenema hyssopifolium* G.Don (Gentianaceae) in Carbon Tetrachloride- Induced Hepatotoxicity in Rats. Trop J Pharm Res 2010; 9: 157-163.
176. Upadhyay UM, Goyal RK. Efficacy of *Enicostemma littorale* in type 2 diabetic patients. Phytother Res 2004; 18: 233-235.
177. Bhatt NM, Barua S, Gupta S. Protective Effect of *Enicostemma littorale* Blume on Rat Model of Diabetic Neuropathy. American J Infect Dis 2009; 5: 99-105.1: 187-190.
178. Gite VN, Pokharkar RD, Chopade VV, Takate SB. Evaluation of physicochemical standardization parameter of *Enicostemma axillare*. J Biosci Tech. 2010;1(4):187-90.
179. Mokashi P, Khanna A, Pandita N. Flavonoids from *Enicostema littorale* blume enhances glucose uptake of cells in insulin resistant human liver cancer (HepG2) cell line via IRS-1/PI3K/Akt pathway. Biomedicine & Pharmacotherapy. 2017 Jun 1; 90:268-277.
180. Gupta RS, Singh D. Hepatomodulatory role of *Enicostemma littorale* Blume against oxidative stress induced liver injury in rats. Afr J Agric Res 2007; 2: 131-138.
181. Vishwakarma SL, Goyal RK. Hepatoprotective activity of *Enicostemma littorale* in CCl<sub>4</sub>-induced liver damage. Journal of Natural Remedies. 2004 Jun 1;4(2):120-126.
182. Jaishree V, Badami S, Bhojraj S. In vitro Antioxidant Activity of *Enicostemma axillare*. JHSci 2008; 54: 524-528.
183. Arivukkarasu R, Rajasekaran A, Muruges S. Anti-inflammatory activity of alcoholic extract of *Adenema hyssopifolium* G. Don in acute and chronic experimental models in albino rats. J Appl Biosci. 2009 Sep 2; 19:1049-1053.

## References

---

184. Deore SL, Khadabadi SS, Bhagure L, Ghorpade DS. In vitro antimicrobial and antioxidant studies on *Enicostemma axillare* (Lam.) Raynal. leaves. NPR. 2008. 7: 409-412.
185. Alagiri A, kokila Mookiah T, Ganesan A, Kumar M, Thigarajan RA, Ramasamy A. Evaluation of Anti-Cancer Activity in Methanolic Extract of *Enicostemma Littorale* on Den Induced Hepatocarcinogenesis in Rats. Indo American Journal of Pharmaceutical Research. 2018;8(03), 1537-1554.
186. Batool R, Khan MR, Sajid M, Ali S, Zahra Z. Estimation of phytochemical constituents and in vitro antioxidant potencies of *Brachychiton populneus* (Schott & Endl.) R. Br. BMC chemistry. 2019 Dec; 13:1-5.
187. Hamid HK, Kadhim EJ. Extraction, isolation and characterization of Pyrrolizidine Alkaloids present in *Senecio vulgaris* Linn grown in Iraq. Journal of pharmacognosy and phytochemistry. 2016; 5(6):28-37.
188. Ding W, Chen X, Yang L, Chen Y, Song J, Bu W, Feng B, Zhang M, Luo Y, Jia X, Feng L. Combination of ShuangDan capsule and sorafenib inhibits tumor growth and angiogenesis in hepatocellular carcinoma via PI3K/Akt/mTORC1 pathway. Integrative Cancer Therapies. 2022 Mar; 21:15347354221078888.
189. Nguyen TK, Phung HH, Choi WJ, Ahn HC. Network Pharmacology and Molecular Docking Study on the Multi-Target Mechanisms of *Aloe vera* for Non-Alcoholic Steatohepatitis Treatment. Plants (Basel). 2022 Dec 19; 11(24):3585.
190. Saleem Basha S, Tripathi D, Koora S, Satyanarayana K, Jayaraman S. Molecular docking analysis of potential compounds from an Indian medicinal soup "kabasura kudineer" extract with IL-6. Bioinformation. 2021 May 31; 17(5):568-572.
191. Vistica VT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. 1991. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 51(10):2515-2520.
192. Bort A, Spínola E, Rodríguez-Henche N, Díaz-Laviada I. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget. 2017 Oct 10; 8(50):87684
193. Wu WD, Chen PS, Omar HA, Arafa ES, Pan HW, Jeng J, Hung JH. *Antrodia cinnamomea* boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Scientific reports. 2018 Aug 27; 8(1):1-3.

## References

---

194. Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C. Clonogenic assay of cells in vitro. *Nature protocols*. 2006 Dec; 1(5):2315-2319.
195. Shirazi FH, Piri M, Keshavarz S, Gholami S, Hosseini SH, Noubarani M, Andalib S, Kamalinejad M, Adiban H, Eskandari MR. Olive fruit (*Olea europaea* L.): Chemopreventive effect in the rat model of hepatocellular carcinoma. *PharmaNutrition*. 2018 Dec 1;6(4):207-214.
196. OECD. Acute oral toxicity-acute toxic class method. OECD Guidelines for the Testing of Chemicals (No. 423). (Adopted on 17 December, 2011). Paris: OECD; 2001
197. Malik S, Bhatnagar S, Chaudhary N, Katare DP, Jain SK. DEN+ 2-AAF-induced multistep hepatotumorigenesis in Wistar rats: supportive evidence and insights. *Protoplasma*. 2013 Feb;250(1):175-183.
198. Minervino AH, Araújo CA, Soares HS, Picanço EM, Silva YR, Mori CS, Gennari SM, Barrêto Júnior RA, Ortolani EL. Serum Biochemistry of Greater Rhea (*Rhea americana*) in Captivity in the Northeast of Brazil. *Animals*. 2023 Jun 25; 13(13):2103.
199. Mansour MA, Bekheet SA, Al-Rejaie SS, Al-Shabanah OA, Al-Howiriny TA, Al-Rikabi AC, Abdo AA. Ginger ingredients inhibit the development of diethylnitrosoamine induced premalignant phenotype in rat chemical hepatocarcinogenesis model. *Biofactors*. 2010 Nov; 36(6):483-490.
200. Kyei-Barffour I, Kwarkoh RK, Acheampong DO, Brah AS, Akwetey SA, Aboagye B. Alkaloidal extract from *Carica papaya* seeds ameliorates CCl<sub>4</sub>-induced hepatocellular carcinoma in rats. *Heliyon*. 2021 Aug 1; 7(8):e07849.
201. Chen Z, Li S, Han L, He X. Optimized protocol for an inducible rat model of liver tumor with chronic hepatocellular injury, inflammation, fibrosis, and cirrhosis. *STAR protocols*. 2021 Mar 19; 2(1):100353.
202. Wang L, Huang W, Zhan J. Grape seed proanthocyanidins induce autophagy and modulate survivin in HepG2 cells and inhibit xenograft tumor growth in vivo. *Nutrients*. 2019 Dec; 11(12):2983.
203. Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J, Liu J, Gao J, Fang D, Rao Z. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. *Clinics*. 2012 Sep; 67(9):1093-1099.
204. Seyhoun I, Hajighasemlou S, Muhammadnejad S, Ai J, Nikbakht M, Alizadeh AA, Hosseinzadeh F, Mirmoghtadaei M, Seyhoun SM, Verdi J. Combination therapy of

## References

---

- sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma. *Journal of Cellular Physiology*. 2019 Jun; 234(6):9495-9503.
205. Li H, Jiang D, Zhang L, Wu J. Inhibition of tumor growth of human hepatocellular carcinoma HepG2 cells in a nude mouse xenograft model by the total flavonoids from *Arachniodes exilis*. *Evidence-Based Complementary and Alternative Medicine*. 2017 Jan 1; 2017.
206. Gu Q, Zhang B, Sun H, Xu Q, Tan Y, Wang G, Luo Q, Xu W, Yang S, Li J, Fu J, Chen L, Yuan S, Liang G, Ji Q, Chen SH, Chan CC, Zhou W, Xu X, Wang H, Fang DD. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. *Oncotarget*. 2015 Aug 21; 6(24):20160-20176.
207. Huynh H, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). *Journal of hepatology*. 2010 Jan 1; 52(1):79-87.
208. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. *Cancer research*. 2006 Dec 15; 66(24):11851-11858.
209. Kim MN, Lee SM, Kim JS, Hwang SG. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. *Cancer Chemotherapy and Pharmacology*. 2019 Oct; 84(4):809-817.
210. Cui Z, Wang H, Li S, Qin T, Shi H, Ma J, Li L, Yu G, Jiang T, Li C. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism. *Journal of Pharmacological Sciences*. 2022 Jan 1; 148(1):73-85.
211. Wang L, Huang W, Zhan J. Grape seed proanthocyanidins induce autophagy and modulate survivin in HepG2 cells and inhibit xenograft tumor growth in vivo. *Nutrients*. 2019 Dec 6; 11(12):2983.
212. Zhang Y, Lv P, Ma J, Chen N, Guo H, Chen Y, Gan X, Wang R, Liu X, Fan S, Cong B. *Antrodia cinnamomea* exerts an anti-hepatoma effect by targeting PI3K/AKT-mediated

## References

---

- cell cycle progression in vitro and in vivo. *Acta Pharmaceutica Sinica B*. 2022 Feb 1;12(2):890-906.
213. Ding W, Chen X, Yang L, Chen Y, Song J, Bu W, Feng B, Zhang M, Luo Y, Jia X, Feng L. Combination of ShuangDan capsule and sorafenib inhibits tumor growth and angiogenesis in hepatocellular carcinoma via PI3K/Akt/mTORC1 pathway. *Integrative Cancer Therapies*. 2022 Mar; 21:15347354221078888.
214. Rajpoot K, Mishra RN. *Boerhaavia diffusa* roots (Punarnava mool)–review as rasayan (rejuvenator/antiaging). *Int J Res Pharm Biomed Sci*. 2011 Oct; 2:1451-1460.
215. Saranya R, Thirumalai T, Hemalatha M, Balaji R, David E. Pharmacognosy of *Enicostemma littorale*: A review. *Asian Pacific journal of tropical biomedicine*. 2013 Jan 1;3(1):79-84.
216. Zamir R, Hosen A, Ullah MO, Nahar N. Microbial and heavy metal contaminant of antidiabetic herbal preparations formulated in Bangladesh. *Evidence-Based Complementary and Alternative Medicine*. 2015 Oct 26; 2015.
217. United States Pharmacopeial Convention, USP-NF 37-32, 2014
218. Rosidi B, Priyatno D, Putra TP, Yusuf I. Metformin Induces a Caspase 3-Unrelated Apoptosis in Human Colorectal Cancer Cell Lines HCT116 and SW620. *Cancer Management and Research*. 2023:475-485.
219. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. *Molecular cancer*. 2019 Feb 19; 18(1):26.
220. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. *Oncology*. 2005; 69 Suppl 3:4-10.
221. Huynh H, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). *Journal of hepatology*. 2010 Jan 1; 52(1):79-87.
222. Shi S, Rao Q, Zhang C, Zhang X, Qin Y, Niu Z. Dendritic cells pulsed with exosomes in combination with PD-1 antibody increase the efficacy of sorafenib in hepatocellular carcinoma model. *Transl Oncol*. 2018; 11:250-258.
223. Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. *Nat Med*. 2014; 20:1138-1146.

## References

---

224. Zhai, B. & Sun, X. Y. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. *World journal of hepatology* 5, 345–352 (2013).
225. Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X. Targeting KDM1A attenuates Wnt/ $\beta$ -catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. *Cancer letters*. 2017 Jul 10; 398:12-21.
226. Shi J, Wang X, Lyu L, Jiang H, Zhu HJ. Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes. *Drug metabolism and pharmacokinetics*. 2018 Apr 1; 33(2):133-140.
227. Alharbi SF, Althbah AI, Mohammed AH, Alrasheed MA, Ismail M, Allemailem KS, Alnuqaydan AM, Baabdullah AM, Alkhalifah A. Microbial and heavy metal contamination in herbal medicine: a prospective study in the central region of Saudi Arabia. *BMC Complementary Medicine and Therapies*. 2024 Jan 2; 24(1):2.
228. Luo L, Wang B, Jiang J, Fitzgerald M, Huang Q, Yu Z, et al. Heavy Metal Contaminations in Herbal Medicines: determination, Comprehensive Risk assessments, and solutions. *Front Pharmacol*. 2021; 11: 595335.
229. Nutrition C for, FS. and A. FDA's Testing of Cosmetics for Arsenic, Cadmium, Chromium, Cobalt, Lead, Mercury, and Nickel Content. FDA [Internet]. 2022 Mar 3 [cited 2023 Apr 8]; Available from: <https://www.fda.gov/cosmetics/potential-contaminants-cosmetics/fdas-testing-cosmetics-arsenic-cadmiumchromium-cobalt-lead-mercury-and-nickel-content>.
230. Duan T, Sun W, Zhang M, Ge J, He Y, Zhang J, Zheng Y, Yang W, Shen HM, Yang J, Zhu X. Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile. *Scientific reports*. 2017 Mar 6; 7(1):1-3.
231. Zayed MN, Aly HF, Moneim El-Mezayen HA, El-Salamony HE. Effect of co-administration of Bee honey and some chemotherapeutic drugs on dissemination of hepatocellular carcinoma in rats. *Toxicol. Rep*. 6: 875-888.
232. Frank D, Savir S, Gruenbaum BF, Melamed I, Grinshpun J, Kuts R, Knyazer B, Zlotnik A, Vinokur M, Boyko M. Inducing acute liver injury in rats via carbon tetrachloride

## References

---

- (CCl4) exposure through an orogastric tube. *JoVE (Journal of Visualized Experiments)*. 2020 Apr 28(158):e60695.
233. Li J, Wang X, Ren M, He S, Zhao Y. Advances in experimental animal models of hepatocellular carcinoma. *Cancer Medicine*. 2023 Jul; 12(14):15261-15276.
234. Sewduth RN, Georgelou K. Relevance of Carcinogen-Induced Preclinical Cancer Models. *Journal of Xenobiotics*. 2024 Jan 5; 14(1):96-109.
235. Irtenkauf SM, Sobiechowski S, Hasselbach LA, Nelson KK, Transou AD, Carlton ET, Mikkelsen T, Decarvalho AC. Optimization of glioblastoma mouse orthotopic xenograft models for translational research. *Comparative medicine*. 2017 Aug 1; 67(4):300-314.
236. Lai P.B., Chi T.Y., Chen G.G. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. *Apoptosis*. 2007; 12(2):387–393.
237. Liu J., Ma Q., Zhang M., Wang X., Zhang D., Li W. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. *Eur J Cancer (Oxford, Engl)* 2012; 48(15):2328–2338.
238. Manu K.A.; Kuttan G. (2009). "Punarnavine induces apoptosis in B16F-10 melanoma cells by inhibiting NF-kappaB signaling". *Asian Pacific Journal of Cancer Prevention*. **10** (6): 1031–1037
239. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. *Chromosoma*. 2018 Jun; 127:175-186.
240. He Y, Liu F, Mou S, Li Q, Wang S. Prognostic analysis of hepatocellular carcinoma on the background of liver cirrhosis via contrast-enhanced ultrasound and pathology. *Oncology Letters*. 2018 Mar 1; 15(3):3746-3752.
241. Schlüter A, Weller P, Kanaan O, Nel I, Heusgen L, Höing B, Haßkamp P, Zander S, Mandapathil M, Dominas N, Arnolds J. CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma. *BMC cancer*. 2018 Dec; 18:1-8.
242. Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. *J Hepatocell Carcinoma*. 2020 Apr 23; 7:77-89.

## References

---

243. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. *Molecular cancer*. 2019 Feb 19; 18(1):26.
244. Yoo HH, Kwon SW, Park JH. The cytotoxic saponin from heat-processed *Achyranthes fauriei* roots. *Biological and Pharmaceutical Bulletin*. 2006; 29(5):1053-1055.
245. Tan Z, Li X, Chen X, Wang L, Chen B, Ren S, Zhao M. Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma. *Heliyon*. 2024 Jan 15; 10(1): e23931.
246. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. *Jama*. 2010 Nov 17; 304(19):2154-2160.
247. Cheng Y, Luo R, Zheng H, Wang B, Liu Y, Liu D, Chen J, Xu W, Li A, Zhu Y. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. *Oncotarget*. 2017 Apr 4; 8(14):23265.
248. Kim C, Baek SH, Um JY, Shim BS, Ahn KS. Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTP $\epsilon$  and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. *BMC nephrology*. 2016 Dec; 17:1-3.
249. Ku CY, Wang YR, Lin HY, Lu SC, Lin JY. Corosolic acid inhibits hepatocellular carcinoma cell migration by targeting the VEGFR2/Src/FAK pathway. *PLoS One*. 2015 May 15; 10(5):e0126725.
250. S. K. Sharma, N. Vasudeva, and M. Ali, "A new aliphatic acid from *Achyranthes aspera* Linn. roots," *Indian Journal of Chemistry B: Organic and Medicinal Chemistry*, vol. 48, no. 8, pp. 1164–1169, 2009.
251. Zhang X., Lin D., Jiang R., Li H., Wan J., Li H. Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition. *Oncol. Rep*. 2016; 36:271–278.
252. Iriti M., Kubina R., Cochis A., Sorrentino R., Varoni E.M., Kabała-Dzik A., Azzimonti B., Dziedzic A., Rimondini L., Wojtyczka R.D. Rutin, a quercetin glycoside, restores chemosensitivity in human breast cancer cells. *Phytother. Res*. 2017;31:1529–1538

## References

---

253. Huang Y., Sun Y., Wang W.-W., Zhang L. Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells. *Am. J. Transl. Res.* 2018;10:4183
254. Zeng A., Liang X., Zhu S., Liu C., Wang S., Zhang Q., Zhao J., Song L. Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF- $\kappa$ B signaling pathway. *Oncol. Rep.* 2021; 45:717–727.